FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094699495> ?p ?o ?g. }

• W3094699495 endingPage "6" @default.
• W3094699495 startingPage "5" @default.
• W3094699495 abstract "Introduction: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy (TMA) resulting from severe ADAMTS13 deficiency, which is generally treated with therapeutic plasma exchange (PLEX). Although ADAMTS13 activity is often assayed to differentiate TTP from TMAs not requiring PLEX, technical and logistical constraints often limit rapid turnaround of results, with PLEX initiated based on clinical suspicion of TTP while awaiting ADAMTS13 activity results. We estimated the potential reduction in plasma product use if rapid turnaround ADAMTS13 activity testing were available in our centre. Methods: We reviewed medical records for all Vancouver General Hospital patients with ADAMTS13 activity testing since assay implementation. Patients receiving PLEX but ultimately diagnosed with a disease not requiring PLEX were identified as potentially avoidable PLEX (paPLEX), and their plasma product exposures and related blood product costs were estimated. Laboratory results, ADAMTS13 activity, and PLASMIC scores (a validated clinical tool for TTP diagnosis) of this group were compared to those of newly diagnosed TTP patients (N=35). Results: We identified 16 paPLEX patients, including TMAs secondary to malignant hypertension, infection, hemolytic uremic syndrome, illicit drug use, autoimmune renal disease, and malignancy (Table 1). These patients underwent 104 total PLEX cycles (3-12 per patient, median 6), involving 1,428 plasma units (28-199 per patient, median 71.5) and estimated product-associated costs of $187,759 CAD ($140,889 USD). Median platelet counts were significantly lower in TTP than the paPLEX group (7x109/L versus 38x109/L), as was serum creatinine (98µmol/L versus 224µmol/L). PLASMIC scores indicating low or intermediate likelihood of TTP were observed in 63% of patients receiving paPLEX and 17% of patients with TTP. All patients with TTP had ADAMTS13 activity &lt; 10%, while all patients receiving paPLEX had ADAMTS13 activity ≥ 30%. Conclusions: Unnecessary PLEX carries significant patient blood product exposure risks and system costs that may be circumvented if TTP can be reliably distinguished from other TMAs at the time of initial presentation. In our cohort, ADAMTS13 activity results provided clear separation of these groups and improved upon TTP diagnosis by clinical judgement and PLASMIC scores. Rapid turnaround of ADAMTS13 activity testing results has the potential to reduce the unnecessary costs and blood product exposures resulting from PLEX administration to patients with non-TTP TMAs. Figure 1 Disclosures Smith: Alexion: Other: Participated in an advisory board without receiving financial compensation." @default.
• W3094699495 created "2020-11-09" @default.
• W3094699495 creator A5029868109 @default.
• W3094699495 creator A5033361092 @default.
• W3094699495 creator A5068091732 @default.
• W3094699495 date "2020-11-05" @default.
• W3094699495 modified "2023-10-16" @default.
• W3094699495 title "Rapid Turnaround ADAMTS13 Testing Is Likely to Improve Diagnosis of Thrombotic Thrombocytopenic Purpura and Avoid Unnecessary Plasma Exchange" @default.
• W3094699495 doi "https://doi.org/10.1182/blood-2020-140135" @default.
• W3094699495 hasPublicationYear "2020" @default.
• W3094699495 type Work @default.
• W3094699495 sameAs 3094699495 @default.
• W3094699495 citedByCount "0" @default.
• W3094699495 crossrefType "journal-article" @default.
• W3094699495 hasAuthorship W3094699495A5029868109 @default.
• W3094699495 hasAuthorship W3094699495A5033361092 @default.
• W3094699495 hasAuthorship W3094699495A5068091732 @default.
• W3094699495 hasBestOaLocation W30946994951 @default.
• W3094699495 hasConcept C126322002 @default.
• W3094699495 hasConcept C2777878052 @default.
• W3094699495 hasConcept C2778585876 @default.
• W3094699495 hasConcept C2779134260 @default.
• W3094699495 hasConcept C2780306776 @default.
• W3094699495 hasConcept C2780921031 @default.
• W3094699495 hasConcept C71924100 @default.
• W3094699495 hasConcept C89560881 @default.
• W3094699495 hasConcept C90924648 @default.
• W3094699495 hasConceptScore W3094699495C126322002 @default.
• W3094699495 hasConceptScore W3094699495C2777878052 @default.
• W3094699495 hasConceptScore W3094699495C2778585876 @default.
• W3094699495 hasConceptScore W3094699495C2779134260 @default.
• W3094699495 hasConceptScore W3094699495C2780306776 @default.
• W3094699495 hasConceptScore W3094699495C2780921031 @default.
• W3094699495 hasConceptScore W3094699495C71924100 @default.
• W3094699495 hasConceptScore W3094699495C89560881 @default.
• W3094699495 hasConceptScore W3094699495C90924648 @default.
• W3094699495 hasIssue "Supplement 1" @default.
• W3094699495 hasLocation W30946994951 @default.
• W3094699495 hasOpenAccess W3094699495 @default.
• W3094699495 hasPrimaryLocation W30946994951 @default.
• W3094699495 hasRelatedWork W2002452949 @default.
• W3094699495 hasRelatedWork W2006805735 @default.
• W3094699495 hasRelatedWork W2075323718 @default.
• W3094699495 hasRelatedWork W2092127489 @default.
• W3094699495 hasRelatedWork W2160606302 @default.
• W3094699495 hasRelatedWork W2201449395 @default.
• W3094699495 hasRelatedWork W2946198964 @default.
• W3094699495 hasRelatedWork W2978019642 @default.
• W3094699495 hasRelatedWork W3029498159 @default.
• W3094699495 hasRelatedWork W3159566231 @default.
• W3094699495 hasVolume "136" @default.
• W3094699495 isParatext "false" @default.
• W3094699495 isRetracted "false" @default.
• W3094699495 magId "3094699495" @default.
• W3094699495 workType "article" @default.